Fundraising FoxQuan Capital
Venture capitalShanghai · Seed–Growth · 17 people tracked
Also known as QUAN CAPITAL MANAGEMENT, LLC
Find your way into Quan Capital
Sign up to see every warm intro you have to Quan Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Quan Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Quan Capital positions itself as a company builder in the life sciences, working to identify, incubate and grow future industry leaders. The team describes itself as industry veterans focused on capturing evolving healthcare trends and emerging cutting-edge innovations. As a preferred partner, the firm emphasizes connecting portfolio companies with an extensive network and resources both globally and specifically in China, supporting biotech and therapeutics development.
Source: firm website, verified Oct 13, 2026.
Team · 17 people
from the firm's website & public directories
Dr. Samantha Du is Founding Managing Director of Quan Capital and the Founder, Chairperson, and CEO of Zai Lab, which she started in 2014 and took public on NASDAQ in 2017. She holds a Ph.D. in Biochemistry from the University of Cincinnati and worked at Pfizer, where she contributed to the development of products including two that gained FDA approval, before co-founding Hutchison MediPharma and Hutchison China MediTech (now HUTCHMED). She later joined Sequoia Capital China, where she led healthcare investments and served on public and private boards.
Dr. Marietta Wu is a Managing Director at Quan Capital, a life sciences venture fund with offices in China and the U.S. She co-founded Zai Lab, where she served as Chief Operating Officer, and previously was a Managing Director at BVCF (Boyle) responsible for its Greater China life sciences venture business. Earlier in her career she held strategy roles at Edwards Lifesciences and worked in finance and business development at Eli Lilly. She holds an MD from Shanghai Jiao Tong University School of Medicine, a PhD in medical science from a medical school in Ohio, and an MBA from the University of Michigan Ross School of Business.
Stella Xu is Managing Director of Quan Capital, a life sciences venture fund with offices in China and the US, focusing on cross-border value creation and global investments. Before joining Quan, she held R&D leadership roles at Roche, including VP/Site Head of Roche Innovation Center Shanghai, and earlier led healthcare management consulting engagements at McKinsey in the US. She holds a Ph.D. in Immunology from Northwestern University and a B.S. in Biophysics from Peking University.
Yingying Yang is a Partner at Quan Capital, based in the firm's Shanghai office, which she joined in 2017. She previously worked in Sanofi China's strategy planning group on pipeline prioritization and external licensing/M&A, and earlier as an associate consultant at L.E.K. Consulting covering healthcare and pharmaceuticals. She holds a Bachelor in Economics from Fudan University, an MSc in Finance from Imperial College London, and a dual Bachelor in Pharmacology from Shanghai Jiaotong University School of Medicine.
Dr. Harald Reinhart joined Quan Capital as a Venture Partner in 2025 and is CEO of Allphase Pharma Consulting LLC, as well as Adjunct Clinical Professor of infectious diseases at Yale School of Medicine. Before retiring in 2024, he led Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab, and previously held clinical development roles at Shionogi US, Novartis, and Bayer, working on approvals for compounds including ospemifene, Coartem, Famvir, Sebivo, and Cubicin. He holds a medical degree from the University of Würzburg and is board-certified in internal medicine and infectious diseases.
John Wong was a core member of Boston Consulting Group's Health Care practice and chairman of its Asia-Pacific region, and served on BCG's Global Executive and Operating committees. He focuses on the biopharmaceutical and medtech sectors, working with global pharmaceutical and medtech companies in Asia and local biopharmaceutical companies in China. Before joining BCG in 1982, he worked in R&D at Milliken Research, and he holds degrees from Imperial College London, MIT, and Harvard Business School.
Dr. Rick Xu is a Venture Partner at Quan Capital, which he joined in 2021, and has advised and acted as interim CMO for several of the firm's portfolio companies. He currently serves as Chief Medical Officer of Oricell Therapeutics and was previously the founding Chief Medical Officer of InnoCare Pharma (HKEX: 09969), with roughly 30 years in global clinical development at Roche/Genentech, Pfizer, and Sterling Winthrop. He earned his medical degree from Harbin Medical University, completed a Gastroenterology fellowship at Truman Medical Center, and holds a Ph.D. in Biopharmaceuticals from SUNY at Buffalo.
Dr. Angela Shen is a Senior Advisor at Quan Capital and Vice President of Strategic Innovation Leaders at Mass General Brigham, where she works on translational medicine, clinical development, and regulatory affairs with a focus on gene and cell therapy. She previously served as Chief Medical Officer at biotech companies including Arcellx, NKarta, and Arvinas, acting CMO at Tizona, and held oncology drug development roles at Novartis, Exelixis, and Johnson & Johnson. At Novartis she led the clinical team behind the first multi-site registration CAR-T trial, resulting in the approval of Kymriah. She holds a BS from Rensselaer, an MD from Albany Medical College, and an MBA from NYU Stern.
Peter Wirth has served as Chairman of the board of Syros Pharmaceuticals since 2017 and previously chaired FORMA Therapeutics Holdings LLC until its 2022 acquisition by Novo Nordisk, as well as serving as a director of Zai Lab Limited. He co-founded Lysosomal Therapeutics and held senior executive roles at Genzyme Corporation, including Executive Vice President of Legal and Corporate Development and Chief Risk Officer, and spent over 20 years as a partner and head of the biotechnology practice at Palmer & Dodge LLP. He holds a J.D. from Harvard Law School and a B.A. in Political Science from the University of Wisconsin at Madison.
Zhanghang Yan is a Vice President at Quan Capital, working on investment idea generation and portfolio management. He previously spent four years as an associate at SDIC Venture Capital, focusing on biotech and IVD, and his work includes healthcare industry research, due diligence, and deal structuring. He holds a B.S. in Biology from Nanjing University and an M.S. in Genetics and Genomics from the University of California, Davis.
What they invest in
from 23 of 29 portfolio companiesBiotech ×21Healthtech ×14AI & Machine Learning ×4Digital Health ×4Medical Devices ×4Deep Tech ×3Data & Infrastructure ×1Defense Tech ×1
HQs:United States×14China×4
Who they back
founder profiles across 11 portfolio companiesFounding team size:solo founder×62 founders×5
Investments · 29 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12023 · 22022 · 12021 · 32018 · 19 dated
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in
BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)
Co-investorsForesite CapitalOrbiMedPontifax Venture CapitalaMoonNovartis Venture FundPureTech Health
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsAvoro Capital AdvisorsRA CapitalSR One Capital ManagementWellington ManagementWestRiver Group
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsSofinnova Ventures+4 more
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersPivotal Life SciencesSR One Capital Management+3 more
Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersSofinnova PartnersAstellas Venture Management LLCEMBL VenturesFuture Planet CapitalAvlar BioVentures+3 more
Adcentrx Therapeutics is a biotech company focused on the discovery and clinical development of antibody-drug conjugates (ADCs) for oncology.
BiotechHealthtech
Hui Li(Founder, President & CEO)in
Co-investorsEight Roads VenturesF-Prime CapitalDelta Capital
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLAVLilly Asia Ventures3E Bioventures Capital3H Health InvestmentSherpa Healthcare PartnersYuanBio Venture Capital
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Samsara BioCapitalSixty Degree CapitalSolasta VenturesSR One Capital Management+4 more
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMed+6 more
Centrexion develops therapies for the treatment of pain, focusing on the design and execution of clinical trials for pain drug development.
BiotechHealthtechBaltimore, US
James N. Campbell(President, Chief Scientific Officer)inKerrie L. Brady(Executive Officer)inGregg Beloff(Executive Officer)Jeffrey B. Kindler(Chief Executive Officer)inCharles Oh(Chief Medical Officer)inSmital Shah(Acting CBO)in
Co-investorsCatalio Capital Management, LPEFung CapitalNew Enterprise Associates (NEA)6 Dimensions CapitalAvoro Capital AdvisorsExome Asset Management
Caidya is a global full-service clinical research organization (CRO) that supports biopharmaceutical companies with clinical trial design, execution, and patient recruitment across more than 40 countries.
BiotechDigital HealthHealthtech
Co-investorsQiming Venture Partners
iCarbonX (碳云智能) is a digital life company using artificial intelligence and silicon-based biochip technology for drug discovery, precision diagnostics, and innovation across genomics, proteomics, and digital health.
AI & Machine LearningBiotechDigital HealthShenzhen, CN
Jun Wang(Founder & CEO)Yingrui Li(Chief Scientist & Co-founder)Jie Zhao(Chief Financial Officer)Ning Tang(Head of Diagnostics)
Co-investorsTencent HoldingsThird Point Ventures
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundOUP (Osage University Partners)Pfizer Venture InvestmentsBain Capital Life Sciences+3 more
Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.
BiotechHealthtechCambridge, US
Wenru Song(Founder)in
Co-investorsForesite CapitalVivo CapitalIkarian Capital
Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer.
BiotechDeep TechHealthtechShanghai, CN
Helen Yang(Founder)inIris Huangin
Co-investorsQiming Venture PartnersVivo CapitalRTW Investments L.P.
Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.
BiotechDigital HealthDoylestown, US
Chengzao Sun(Founder)inSandeep Somani(Founder)in
Co-investorsForesite CapitalRA CapitalLAVOrbiMedVenrock
Sail Biomedicines develops RNA-based medicines using a platform integrating Endless RNA and targeted nanoparticle delivery technology.
AI & Machine LearningBiotechDeep TechCambridge, US
John Mendlein(Executive Chairman)
Co-investorsFlagship PioneeringNextech Invest
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsAisling CapitalARCH Venture PartnersAlexandriaAlly Bridge GroupBain CapitalBain Capital Life Sciences+11 more
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)inMatthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)inThomas W. Dubensky, Jr.(Executive Officer, Director)Thomas Woiwode(Director)Geoffrey Nichol(Director)
Co-investorsF-Prime CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Roche Venture FundVersant Ventures
Therorna develops circular RNA-based therapeutic candidates and preventive medicines for diseases with unmet clinical needs.
AI & Machine LearningBiotechDeep TechHealthtechBeijing, CN
Co-investorsCenova Capital3H Health InvestmentMSA CapitalSherpa Healthcare Partners
Windward delivers AI-powered operational intelligence for maritime security and commercial applications, fusing behavioral analytics and multi-sensor data to detect threats and opportunities.
AI & Machine LearningData & InfrastructureDefense TechTel Aviv
Amiad Daniel(Executive Officer, Director)Matan Peled(Founder)inAmi Daniel(Founder)
BoardDov Gatmon(Director)Patrick Poon(Director)Eden Shochat(Director)in
Co-investorsAlephFTV CapitalThompson Hutton, LLCJanus Henderson InvestorsPivotal Life SciencesQiming Venture Partners+3 more
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedRA CapitalSanofi VenturesSR One Capital ManagementJanus Henderson InvestorsNovo Holdings+3 more
Zidan Medical develops an endobronchial radiofrequency ablation system, using a small flexible RF catheter with "virtual electrode" forward-throw technology to deliver targeted, temperature-controlled energy to destroy lung lesions.
HardwareHealthtechMedical DevicesCupertino, US
Don Tanaka(VP of Clinical Research)inShashank Raina(VP of R&D)in
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ARMO BioSciencesEluminexbioMedxtmcOriCellRareStone GroupSilexon
Exits · 5
5 IPOs · showing 4Adicet BioNASDAQ: ACETDesigntxNASDAQ: DSGNNextCureNASDAQ: NXTCZenas BiopharmaNASDAQ: ZBIO
Portfolio news
latest coverage across their companies
Kira Pharmaceuticals · pharmexec.com · Aug 6, 2026
Adicet Bio · stocktitan.net · Aug 5, 2026
NextCure · grafa.com · Jul 14, 2026
Arcellx · startupintros.com · Jul 13, 2026
Tempest Therapeutics · stocktitan.net · Jun 1, 2026
Windward Bio · finsmes.com · May 5, 2026
Oricell Therapeutics · finsmes.com · Apr 10, 2026
Frequently asked questions
- How many investments has Quan Capital made?
- Quan Capital has 29 tracked investments, 5 of which have exited, including 2 dated in the last 24 months.
- What stage does Quan Capital invest at?
- Quan Capital invests at the Seed, Series A, Series B, Growth stages.
- What sectors does Quan Capital focus on?
- Quan Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Quan Capital located?
- Quan Capital is headquartered in Shanghai, CN.
- Who does Quan Capital co-invest with?
- Quan Capital most often shares deals with New Enterprise Associates (NEA), SR One Capital Management, Foresite Capital, among 50 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is an independent manager of venture capital funds and the listed investment company Quest for Growth, backing innovative companies that use technology as a competitive advantage.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.